# A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

> **NCT04970654** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 110 (actual)

## Conditions studied

- Growth Hormone Deficiency in Children

## Interventions

- **DRUG:** somapacitan
- **DRUG:** Norditropin®

## Key facts

- **NCT ID:** NCT04970654
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-22
- **Primary completion:** 2023-11-17
- **Final completion:** 2023-12-18
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04970654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04970654, "A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04970654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*